Refractory migraine profile in CGRP-monoclonal antibodies scenario

Marcello Silvestro, Alessandro Tessitore, Fabrizio Scotto di Clemente, Giorgia Battista, Gioacchino Tedeschi, Antonio Russo, Marcello Silvestro, Alessandro Tessitore, Fabrizio Scotto di Clemente, Giorgia Battista, Gioacchino Tedeschi, Antonio Russo

Abstract

Objective: Refractory migraine (Ref-M) represents a conundrum that headache experts have to face with. We aim to investigate whether a peculiar profile may characterize patients with Ref-M according to 2020 European Headache Federation criteria. Furthermore, to substantiate a dysfunctional dopaminergic pathway involvement in these patients, we explored the effectiveness of olanzapine.

Materials & methods: Eighty-four patients (fitting previous Ref-M criteria of the 2014) were treated with erenumab for six months. Differences between clinical and demographic features of responder (Ref-M according to 2014 criteria) and not-responder (Ref-M according to 2020 criteria) patients to CGRP-mAbs were investigated and their predictive values assessed. In fifteen patients with Ref-M not responders to CGRP-mAbs, olanzapine was administered (5 mg/die) for 3 months and frequency and pain intensity of migraine attacks were estimated.

Results: Patients with Ref-M not responsive to CGRP-mAbs (29/84) when compared with Ref-M responsive to CGRP-mAbs showed higher baseline frequency of migraine attacks, medication overuse and pain catastrophizing scale (PCS) scores. Logistic regression analyses showed that frequency of attacks, medication overuse and PCS score represent independent negative predictors of CGRP-mAbs response. A ≥50% reduction of headache days/month was observed after olanzapine treatment in 67% of patients with Ref-M not responsive to CGRP-mAbs.

Conclusions: We outline that higher frequency of migraine attacks, medication overuse and pain catastrophizing characterize patients with Ref-M not responsive to CGRP-mAbs. In this frame, olanzapine effectiveness on frequency and pain intensity of migraine attacks supports the hypothesis that migraine refractoriness may be subtended by a prominent involvement of the dopaminergic pathway.

Keywords: antipsychotic drugs; chronic migraine; monoclonal antibodies; olanzapine; refractory.

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MS has received speaker honoraria from Novartis and Lilly. AT has received speaker honoraria from Novartis, Schwarz Pharma/UCB, Lundbeck, Abbvie and Glaxo. GT has received speaker honoraria from Sanofi‐Aventis, Merck Serono, Bayer Schering Pharma, Novartis, Biogen‐Dompe´ AG, Teva and Lilly; has received funding for travel from Bayer Schering Pharma, Biogen‐Dompe´ AG, Merck Serono, Novartis, and Sanofi Aventis; and serves as an associate editor of Neurological Sciences. AR has received speaker honoraria from Allergan, Lilly, Novartis and Teva and serves as an associate editor of Frontiers in Neurology (Headache Medicine and Facial Pain session). The other authors have nothing to declare.

© 2021 The Authors. Acta Neurologica Scandinavica published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
Comparison of frequency of monthly headache attacks and pain intensity during headache attacks in patients with Ref‐M before and after 3‐month olanzapine treatment

References

    1. Schulman EA, Brahin EJ. Refractory headache: historical perspective, need, and purposes for an operational definition. Headache. 2008;48(6):770‐777.
    1. D'Antona L, Matharu M. Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain. 2019;23(20).
    1. Goadsby PJ, Schoenen J, Ferrari MD, et al. Towards a definition of intractable headache for use in clinical practice and trials. Cephalalgia. 2006;26:1168‐1170.
    1. Martelletti P, Katsarava Z, Lampl C, et al. Refractory chronic migraine: a consensus statement on clinical definition from the European headache federation. J Headache Pain. 2014;15:47.
    1. Schulman EA, Lake AE, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: proposed criteria from the refractory headache special interest section of the American headache society. Headache. 2008;48:778‐782.
    1. Silberstein SD, Dodick DW, Pearlman S. Defining the pharmacologically intractable headache for clinical trials and clinical practice. Headache. 2010;50:1499‐1406.
    1. Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain. 2020;21(1):76.
    1. Torres‐Ferrús M, Ursitti F, Alpuente A, et al. From transformation to chronification of migraine: pathophysiological and clinical aspects. J Headache Pain. 2020;21:42.
    1. Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence‐based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;30;20(1):92.
    1. Akdag Uzun Z, Kurt S, Karaer UH. The relationship with restless legs syndrome, fibromyalgia, and depressive symptoms in migraine patients. Neurol Sci. 2018;39(8):1409‐1414.
    1. Silberstein SD, Peres MF, Hopkins MM, et al. Olanzapine in the treatment of refractory migraine and chronic daily headache. Headache. 2002;42(6):515‐518.
    1. Jimenez XF, Sundararajan T, Covington EC. A systematic review of atypical antipsychotics in chronic pain management: olanzapine demonstrates potential in central sensitization, fibromyalgia, and headache/migraine. Clin J Pain. 2018;34(6):585‐591.
    1. Headache classification committee of the international headache society (IHS) . The International Classification of Headache Disorders. 3rd edition. Cephalalgia. 2018;38:1‐211.
    1. Steiner TJ, Martelletti P. Aids for management of common headache disorders in primary care. J Headache Pain. 2007;8(Suppl 1):S2.
    1. Silberstein S, Tfelt‐Hansen P, Dodick DW, et al. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28:484‐495.
    1. Silberstein S, Tfelt‐Hansen P, Dodick DW, et al. Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia. 2008;28(5):484‐495.
    1. Russo A, Silvestro M, Scotto di Clemente F, et al. Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real‐world experience. J Headache Pain. 2020;21(1):69.
    1. Russo A, Silvestro M, Garramone F, et al. A subjective cognitive impairments scale for migraine attacks: validation of the Italian version of the MIG‐SCOG. Neurol Sci. 2020;41(5):1139‐1143.
    1. Baskin SM, Lipchik GL, Smitherman TA. Mood and anxiety disorders in chronic headache. Headache. 2006;46(Suppl 3):S76‐S87.
    1. Saper JR. “are you talking to me?” confronting behavioral disturbances in patients with headache. Headache. 2006;46(Suppl 3):S151‐S156.
    1. Freedom T, Evans RW. Headache and sleep. Headache. 2013;53(8):1358‐2136.
    1. Ornello R, Casalena A, Frattale I, et al. Real‐life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):32.
    1. Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13(4):301‐307.
    1. Schiano di Cola F, Caratozzolo S, Liberini P, et al. Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxin‐a treatment. Front Neurol. 2019;10(10):678.
    1. Riederer F, Marti M, Luechinger R, et al. Grey matter changes associated with medication‐overuse headache: correlations with disease related disability and anxiety. World J Biol Psychiatry. 2012;13:517‐525.
    1. Riederer F, Schaer M, Gantenbein AR, et al. Cortical alterations in medication‐overuse headache. Headache. 2017;57:255‐265.
    1. Altamura C, Costa C, Fofi L, et al. Migraineurs’ psychological traits do not influence response to erenumab. Neurol Sci. 2020;41(Suppl 2):467‐468.
    1. Bond DS, Buse DC, Lipton RB, et al. Clinical Pain Catastrophizing in Women With Migraine and Obesity. Headache. 2015;55(7):923‐933.
    1. Santangelo G, Russo A, Trojano L, et al. Cognitive dysfunctions and psychological symptoms in migraine without aura: a cross‐sectional study. J Headache Pain. 2016;17(1):76.
    1. Elman I, Borsook D. Common Brain Mechanisms of Chronic Pain and Addiction. Neuron. 2016;89(1):11‐36.
    1. Sullivan MJ, Thorn B, Haythornthwaite JA, et al. Theoretical perspectives on the relation between catastrophizing and pain. Clin J Pain. 2001;17:52‐64.
    1. Peters ML, Vlaeyen JW, Weber WE. The joint contribution of physical pathology, pain‐related fear and catastrophizing to chronic back pain disability. Pain. 2005;113:45‐50.
    1. Severeijns R, Vlaeyen JW, van den Hout MA, et al. Pain catastrophizing predicts pain intensity, disability, and psychological distress independent of the level of physical impairment. Clin J Pain. 2001;17:165‐172.
    1. Andreou AP, Edvinsson L. Mechanisms of migraine as a chronic evolutive condition. J Headache Pain. 2019;20(1):117.
    1. Noseda R, Borsook D, Burstein R. Neuropeptides and neurotransmitters that modulate thalamo‐cortical pathways relevant to migraine headache. Headache. 2017;57:97‐111.
    1. Barbanti P, Fabbrini G. Migraine and the extrapiramidal system. Cephalalgia. 2002;22:2‐11.
    1. Bussone G, Boiardi A, La Mantia L, et al. Clinical usefulness of a dopaminergic agonist in headache diagnosis. Int J Clin Pharmacol Res. 1986;6:23‐26.
    1. Bès A, Dupui P, Güell A, et al. Pharmacological exploration of dopamine hypersensitivity in migraine patients. Int J Clin Pharmacol Res. 1986;6:189‐192.
    1. Barbanti P, Bronzetti E, Ricci A, et al. Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: A marker for migraine? Neurosci Lett. 1996;207:1‐4.
    1. Barbanti P, Fabbrini G, Ricci A, et al. Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. Cephalalgia. 2000;20:15‐19.
    1. DaSilva AF, Nascimento TD, Jassar H, et al. Dopamine D2/D3 imbalance during migraine attack and allodynia in vivo. Neurology. 2017;88:1634‐1641.
    1. Schoenen J. Is chronic migraine a never‐ending migraine attack? Pain. 2011;152:239‐240.
    1. Maizels M, Aurora S, Heinricher M. Beyond neurovascular: migraine as a dysfunctional neurolimbic pain network. Headache. 2012;52(10):1553‐1565.
    1. Russo A, Silvestro M, Trojsi F, et al. Cognitive networks disarrangement in patients with migraine predicts cutaneous allodynia. Headache. 2020;60(7):1228‐1243.
    1. Belujon P, Grace AA. Dopamine system dysregulation in major depressive disorders. Int J Neuropsychopharmacol. 2017;20:1036‐1046.
    1. Vgontzas A, Pavlović JM. Sleep disorders and migraine: review of literature and potential pathophysiology mechanisms. Headache. 2018;58(7):1030‐1039.
    1. Barbanti P, Aurilia C, Egeo G, et al. Dopaminergic symptoms in migraine: A cross‐sectional study on 1148 consecutive headache center‐based patients. Cephalalgia. 2020;40(11):1168‐1176.
    1. Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol. 2012;14(1):27‐35.
    1. Wöber C, Brücke T, Wöber‐Bingöl C, et al. Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia. 1994;14(3):235‐240.
    1. Bigal ME, Ferrari M, Silberstein SD, et al. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache. 2009;49(Suppl 1):S21‐33.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa